Cai Qun, Duan Jinnan, Ding Liang
Department of Infectious Diseases and Liver Diseases, Ningbo Medical Center Lihuili Hospital, Affiliated Lihuili Hospital of Ningbo University, Ningbo, China.
Department of Infectious Diseases, Shaoxing People's Hospital, Shaoxing, China.
Front Surg. 2022 Jul 21;9:819491. doi: 10.3389/fsurg.2022.819491. eCollection 2022.
Immune-related genes (IRGs) are closely connected to the occurrence and development of tumors. Their influence on the prognosis of patients with HCC, however, remains unclear.
From the TCGA database, we integrated 365 liver cancer tissues and 50 normal tissues to identify differential immune genes related to prognosis. Multivariate COX analysis was used to establish a new prognostic index on account of IRGs, whereby risk score = (Expression level of HSPA40.022) + (Expression level of PSMD140.042) + (Expression level of RBP20.019) + (Expression level of MAPT0.197) + (Expression level of TRAF30.146) + (Expression level of NDRG1(0.006) + (Expression level of NRAS0.027) + (Expression level of IL17D0.075).
The risk score was clearly correlated with an unfavorable survival rate and with clinical characteristics. By integrating the immune-related risk score model with clinical features, a nomogram was constructed to predict the survival rate of HCC patients (1-, 3- and 5-year AUC of 0.721, 0.747 and 0.781, respectively).
We have established a valuable prognostic risk score for HCC patients that may be a better predictor of survival than the present method. With the risk score's strong predictive value for immune cells and functions, it may provide clinical guidance for the diagnosis and prognosis of different immunophenotypes, and provide multiple therapeutic targets for the treatment of HCC patients based on subtype-specific immune molecules.
免疫相关基因（IRGs）与肿瘤的发生和发展密切相关。然而，它们对肝癌患者预后的影响仍不清楚。
从TCGA数据库中，我们整合了365个肝癌组织和50个正常组织，以鉴定与预后相关的差异免疫基因。基于IRGs，采用多变量COX分析建立了一个新的预后指数，其中风险评分=（HSPA4表达水平×0.022）+（PSMD14表达水平×0.042）+（RBP2表达水平×0.019）+（MAPT表达水平×0.197）+（TRAF3表达水平×0.146）+（NDRG1表达水平×0.006）+（NRAS表达水平×0.027）+（IL17D表达水平×0.075）。
风险评分与不良生存率及临床特征明显相关。通过将免疫相关风险评分模型与临床特征相结合，构建了一个列线图来预测肝癌患者的生存率（1年、3年和5年的AUC分别为0.721、0.747和0.781）。
我们为肝癌患者建立了一个有价值的预后风险评分，它可能比目前的方法更能准确预测生存率。鉴于该风险评分对免疫细胞和功能具有强大的预测价值，它可为不同免疫表型的诊断和预后提供临床指导，并基于亚型特异性免疫分子为肝癌患者的治疗提供多个治疗靶点。
